Insmed Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
113,894.00
159,226.00
282,876.00
162,591.00
381,165.00
495,072
Other Current Assets
2,269.00
5,488.00
5,242.00
5,816.00
8,279.00
11,327
Total Current Assets
116,163.00
164,714.00
288,118.00
168,407.00
389,444.00
518,946
Net Property, Plant & Equipment
1,812.00
7,534.00
8,092.00
10,020.00
12,432.00
22,636
Intangible Assets
58,200.00
58,200.00
58,200.00
58,200.00
58,200.00
58,675
Other Assets
323.00
416.00
2,146.00
1,329.00
1,971.00
4,299
Total Assets
176,498.00
230,864.00
356,556.00
237,956.00
462,047.00
604,556
ST Debt & Current Portion LT Debt
3,347.00
-
3,113.00
-
-
Accounts Payable
5,929.00
9,249.00
-
-
-
Other Current Liabilities
7,180.00
10,381.00
19,146.00
27,989.00
44,656.00
Total Current Liabilities
16,456.00
19,630.00
22,259.00
27,989.00
44,656.00
Long-Term Debt
16,338.00
24,856.00
22,027.00
54,791.00
55,567.00
Other Liabilities
380.00
141.00
572.00
693.00
765.00
Total Liabilities
33,174.00
44,627.00
44,858.00
83,473.00
100,988.00
Common Equity (Total)
143,324.00
186,237.00
311,698.00
154,483.00
361,059.00
Total Shareholders' Equity
143,324.00
186,237.00
311,698.00
154,483.00
361,059.00
Total Equity
143,324.00
186,237.00
311,698.00
154,483.00
361,059.00
Liabilities & Shareholders' Equity
176,498.00
230,864.00
356,556.00
237,956.00
462,047.00

About Insmed

View Profile
Address
10 Finderne Avenue
Bridgewater New Jersey 08807
United States
Employees -
Website http://www.insmed.com
Updated 07/08/2019
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.